Ultime notizie per Procure Space ETF (NASDAQ:UFO)

Industrials

Communication Services

Technology

Other

Procure Asset Management

The fund invests, under normal circumstances, at least 80% of its net assets in companies of the underlying index that receive at least 50% of their revenues or profits from space-related businesses. The underlying index is designed to serve as an equity benchmark for a globally traded portfolio of companies that are engaged in space-related business, such as those utilizing satellite technology. The fund is non-diversified.

Echostar Corp

Iridium Satellite Llc

Garminltd.

Globalstar Inc

Trimble Inc.

Mda Space Ltd

Eutelsat Sa

Sky Perfect Jsat Holdings Inc

Rocket Lab Usa Inc

Viasat Inc

Sirius Xm Radio

Intuitive Machines Inc A

Planet Labs PBC

Ast Spacemobile Inc Class A

Procure Space ETF

Rocket,Lab,Building,Sign.,Auckland,,New,Zealand,-,February,8,

Equities

Large Cap

News

Movers

ARKX

RKLB

Electron consegna un altro satellite per il cliente nipponico. L&#39;azienda annuncia anche una collaborazione con la NASA.

Rocket Lab: la terza missione per l&#39;iQPS del Giappone è un successo

CYBR

PANW

Palo Alto Says Transaction Expected To Be Immediately Accretive To Revenue Growth And Gross Margin, Expects Deal To Be Accretive To Free Cash Flow Per Share In 2028 Following The First Full Year Of Realization Of Synergies

Susquehanna analyst Bascome Majors maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Positive and lowers the price target from $260 to $257.

Price Target

Analyst Ratings

Susquehanna Maintains Positive on Union Pacific, Lowers Price Target to $257

Palo Alto Networks To Acquire CyberArk; CyberArk Shareholders To Receive $45 In Cash And 2.2005 Shares Of Palo Alto Networks For Each Cyberark Share

Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) raises FY2025 Adj EPS guidance from $1.40-$1.50 to $1.47-$1.57 vs $1.43 analyst estimate. Raises FY2025 sales outlook from $2.900 billion-$3.100 billion to $3.050 billion-$3.250 billion vs $3.055 billion estimate.

Guidance

NMRK

Newmark Group Raises FY2025 Adj EPS Guidance from $1.40-$1.50 to $1.47-$1.57 vs $1.43 Est; Raises FY2025 Sales Guidance from $2.900B-$3.100B to $3.050B-$3.250B vs $3.055B Est

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations.
NEW YORK and MELBOURNE, Australia, July 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company") is excited to share positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnoea (OSA). With over 900 million people affected globally and no approved oral pharmaceutical treatments currently available, IHL-42X's robust efficacy and exceptional safety profile position it as a potential transformative therapy for OSA patients worldwide. The results confirm statistically significant and clinically meaningful improvements across key endpoints assessed in the study, reinforcing IHL-42x's potential as a best-in-class therapy for patients with OSA.
Compelling Clinical Efficacy The RePOSA Phase 2 trial demonstrated clear statistically and clinically significant improvements across multiple key endpoints for patients receiving IHL-42X compared to placebo, highlighting its potential to reduce OSA severity and enhance patient quality of life:
<ul>
<li>Apnoea-Hypopnoea Index (AHI):&nbsp;The low-dose and high-dose IHL-42X groups achieved a statistically significant reduction in percent change in AHI from baseline compared to placebo (p&lt;0.05), the primary measure of OSA severity. Maximum reductions in AHI were observed at up to 83% for the high-dose group and up to 79% for the low-dose group. Notably, 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved a greater than 30% reduction in AHI, while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%—demonstrating a strong therapeutic response in a substantial subset of the population.</li>
<li>Patient Global Impression of Change (PGI-C) Sleep related impairment: The low-dose IHL-42X group showed statistically significant improvement (p&lt;0.05), reflecting meaningful patient-perceived benefits.</li>
<li>PGI-C Fatigue: Statistically significant improvement in the low-dose group, suggesting enhanced daytime alertness and reduced fatigue.</li>
<li>Oxygen Desaturation Index (ODI): Both low- and high-dose groups demonstrated statistically significant improvements, indicating better oxygenation during sleep.</li>
<li>Patient-Reported Outcomes: IHL-42X led to clinically significant improvements in patient-reported outcome measures, including the Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10), PROMIS Sleep-Related Impairment 8a (PROMIS-SRI 8a), PROMIS Fatigue 7a, and Epworth Sleepiness Scale (ESS) in both low- and high-dose groups, demonstrating enhanced sleep quality, reduced daytime fatigue, and improved daily functioning for patients with OSA.</li>
<li>Polysomnography (PSG) Metrics: IHL-42X drastically improved objective sleep parameters as measured by PSG.
<ul>
<li>Wake After Sleep Onset (WASO): Reduced by 29.8% in the high-dose arm, meaning patients spent less time awake during the night.</li>
<li>AHI During Supine Sleep: Decreased by 30.3% in the high-dose arm, a critical improvement given supine sleep exacerbates apneic events.</li>
</ul>
</li>
</ul>
These results collectively demonstrate IHL-42X's ability to address both objective and subjective aspects of OSA, offering compelling clinical benefits to patients.
Outstanding Safety Profile IHL-42X was well tolerated across both low- and high-dose cohorts. No serious adverse events were reported during the treatment period, and treatment-emergent adverse effects (TEAEs) were infrequent, with the majority being mild or moderate in severity. This excellent safety profile supports IHL-42X's potential for broad patient use.

Biotech

General

IXHL

Incannex Reports Phase 2 Results For IHL-42X, Reducing Sleep Apnea Severity By Up To 83% With Strong Safety Profile

Susquehanna analyst Mehdi Hosseini maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Negative and raises the price target from $68 to $80.

Susquehanna Maintains Negative on Seagate Tech Hldgs, Raises Price Target to $80

Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $12.045 million which beat the analyst consensus estimate of $11.803 million by 2.05 percent. This is a 19.15 percent increase over sales of $10.109 million the same period last year.

Earnings

Earnings Beats

BLFY

Blue Foundry Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $12.045M Beat $11.803M Estimate

Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.25 by 23.02 percent. This is a 40.91 percent increase over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $759.112 million which beat the analyst consensus estimate of $691.281 million by 9.81 percent. This is a 19.85 percent increase over sales of $633.375 million the same period last year.

Newmark Group Q2 Adj. EPS $0.31 Beats $0.25 Estimate, Sales $759.112M Beat $691.281M Estimate

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MOGO

Mogo Seeks Regulatory Approval To Offer Crypto Trading On Its Platform In Canda

Susquehanna analyst Joseph Stauff maintains Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) with a Positive and raises the price target from $15 to $19.

Susquehanna Maintains Positive on Rush Street Interactive, Raises Price Target to $19

Cheer Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHR#NASDAQ">CHR</a>) reported quarterly earnings of $1.04 per share. This is a 15.45 percent decrease over earnings of $1.23 per share from the same period last year. The company reported $70.993 million in sales this quarter. This is a 0.09 percent decrease over sales of $71.055 million the same period last year.

Cheer Holding H1 EPS $1.04 Down From $1.23 YoY, Sales $70.993M Down From $71.055M YoY

Susquehanna analyst Joseph Stauff maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Positive and raises the price target from $65 to $68.

Susquehanna Maintains Positive on Red Rock Resorts, Raises Price Target to $68

Macro Economic Events

Econ #s

Economics

ADP Nonfarm Employment Change (Jul) 104K vs 77K Est.

Susquehanna analyst Christopher Stathoulopoulos maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Positive and raises the price target from $275 to $385.

Susquehanna Maintains Positive on Royal Caribbean Gr, Raises Price Target to $385

Dividends

McKesson Corporation Raises Quarterly Dividend From $0.71 Per Share To $0.82 Per Share

Macro Notification

INDA

President Trump On Truth Social Criticizes India For Being Russia's Largest Buyer Of Energy, Says India Will Be Paying A Tariff Of 25%, Plus A Penalty, Starting On August First

SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) ("Clearmind") has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).
This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the <a href="https://www.globenewswire.com/Tracker?data=WzMieBUpcKTELmzJdun3pRBqoPdppVH_S5B5J_pwT6tzpmg5OSyaGTDD4rVuRN6N-bzYwT9Th7P1asN3P-xVHsKq603wsP_QpSbCHI4Gs3gSJE-cwj9y7l51hW5m9KZ0vZ7s8OfFsSchbPDzg81vLRGYnaOeCKluYTWSipYc1ZM=">World Health Organization</a>, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact <a href="https://www.globenewswire.com/Tracker?data=cTol4e_AfYCo-ujDhmfF7m--at8BfaaGE3VoxjmFDqtnEUbEZ1DkBu_PGuMLBthk-I9gMkmhdZF-lNYYUKWC5ZUcROUkQwNU7JlYh6ZgeOjAiMh_KENZbCe4Ru_UVgyT0SzZ3wfvER9O1RvVxsN4DI2X5CwNaRexgxFvmh1EX9xqAwS_BDjyDO4bz4e-ugsB">more than 30% of the global adult population</a>, according to the article titled "Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons," published in August 2023. Despite the scale of these problems, treatment options remain limited.
According to Clearmind, the novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA.
This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration.

CMND

SPRC

SciSparc And Clearmind File International Patent For Novel Obesity And Liver Disease Treatment Combining MEAI and PEA

Susquehanna analyst Christopher Rolland maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Neutral and raises the price target from $90 to $95.

QRVO

Susquehanna Maintains Neutral on Qorvo, Raises Price Target to $95

Wedbush analyst Scott Devitt downgrades Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) from Outperform to Neutral and maintains the price target from $5900 to $5900.

Downgrades

BKNG

Wedbush Downgrades Booking Holdings to Neutral, Maintains Price Target to $5900

Canaccord Genuity analyst Robert Young maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Buy and raises the price target from $126 to $240.

Canaccord Genuity Maintains Buy on Celestica, Raises Price Target to $240

Comments

Procure Space ETF

Notizie

Ultime notizie per Procure Space ETF (NASDAQ:UFO)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO